Citi initiates Insilico buy/high-risk coverage amid AI drug-creation claims
Citi analysts initiated coverage on Insilico with a buy/high-risk rating, citing sustained preclinical candidate generation since 2021 across multiple therapeutic areas and a test of AI’s expansion of pharma innovation.
Insilico offers one of the clearest tests of whether AI can expand pharma innovation beyond faster molecule design, Citi analysts.
They start coverage with a buy/high-risk rating.
Insilico has sustained preclinical candidate generation since 2021 across multiple therapeutic areas, supporting the re…